John Libbey Eurotext

Mega-dose phenobarbital therapy for super-refractory status epilepticus Volume 17, issue 4, December 2015


  • Figure 1


Departments of Neurology, Laboratory for Neurotherapeutics, Comprehensive Epilepsy Center, Biomedical Research Institute,
1 Seoul National University Hospital,
2 Program in Neuroscience, Seoul National University College of Medicine, Seoul, South Korea
* Correspondence: Sang Kun Lee Department of Neurology, Seoul National University Hospital, 101 Daehang-ro, Chongro-gu, Seoul 110-744, South Korea
a Authors contributed equally.


To evaluate the efficacy and safety of mega-dose phenobarbital (MDPB; enteral or parenteral phenobarbital >10 mg/kg/day) for treating super-refractory status epilepticus (SRSE; continuous or recurrent status epilepticus for ≥24 hours after the onset of continuous anaesthetic treatment) in adult patients.